Natixis Advisors L.P. decreased its position in Core Laboratories (NYSE:CLB) by 23.8% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 83,333 shares of the oil and gas company’s stock after selling 25,989 shares during the period. Natixis Advisors L.P.’s holdings in Core Laboratories were worth $4,357,000 as of its most recent filing with the SEC.
A number of other large investors have also recently bought and sold shares of the business. Greenleaf Trust bought a new position in shares of Core Laboratories during the 2nd quarter valued at approximately $214,000. M Holdings Securities Inc. boosted its holdings in Core Laboratories by 18.6% in the 1st quarter. M Holdings Securities Inc. now owns 4,384 shares of the oil and gas company’s stock worth $302,000 after buying an additional 688 shares during the period. Parametric Portfolio Associates LLC boosted its holdings in Core Laboratories by 8.5% in the 1st quarter. Parametric Portfolio Associates LLC now owns 180,235 shares of the oil and gas company’s stock worth $12,424,000 after buying an additional 14,189 shares during the period. Teacher Retirement System of Texas bought a new position in Core Laboratories in the 2nd quarter worth approximately $8,027,000. Finally, SG Americas Securities LLC boosted its holdings in Core Laboratories by 395.1% in the 2nd quarter. SG Americas Securities LLC now owns 19,275 shares of the oil and gas company’s stock worth $1,008,000 after buying an additional 15,382 shares during the period.
NYSE CLB traded down $0.33 on Friday, hitting $46.65. The stock had a trading volume of 22,701 shares, compared to its average volume of 547,835. Core Laboratories has a 52-week low of $36.61 and a 52-week high of $122.11. The company has a debt-to-equity ratio of 1.83, a quick ratio of 1.41 and a current ratio of 1.80. The company has a market capitalization of $2.02 billion, a price-to-earnings ratio of 20.48, a price-to-earnings-growth ratio of 4.86 and a beta of 1.95. The firm has a 50-day moving average of $42.59 and a 200-day moving average of $55.66.
Core Laboratories (NYSE:CLB) last posted its earnings results on Wednesday, July 24th. The oil and gas company reported $0.46 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.46. Core Laboratories had a net margin of 14.30% and a return on equity of 51.19%. The business had revenue of $169.04 million for the quarter, compared to analysts’ expectations of $173.46 million. During the same period in the prior year, the company posted $0.59 EPS. The business’s revenue for the quarter was down 3.7% compared to the same quarter last year. As a group, research analysts anticipate that Core Laboratories will post 1.75 earnings per share for the current fiscal year.
Several research analysts recently commented on CLB shares. Morgan Stanley cut their price objective on shares of Core Laboratories from $75.00 to $70.00 and set an “equal weight” rating for the company in a report on Friday, July 12th. Bank of America raised shares of Core Laboratories from a “neutral” rating to a “buy” rating and set a $63.00 price objective for the company in a report on Wednesday, July 10th. Piper Jaffray Companies set a $52.00 price objective on shares of Core Laboratories and gave the stock a “hold” rating in a report on Wednesday, June 26th. Royal Bank of Canada set a $77.00 price objective on shares of Core Laboratories and gave the stock a “buy” rating in a report on Wednesday, June 26th. Finally, Citigroup cut their price objective on shares of Core Laboratories from $54.00 to $51.00 and set a “neutral” rating for the company in a report on Wednesday. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and six have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $74.42.
In other news, Director Gregory Barry Barnett bought 1,000 shares of the stock in a transaction on Tuesday, August 13th. The shares were acquired at an average cost of $40.00 per share, for a total transaction of $40,000.00. Following the purchase, the director now directly owns 11,000 shares of the company’s stock, valued at approximately $440,000. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 2.00% of the company’s stock.
Core Laboratories Profile
Core Laboratories N.V. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. The company operates in two segments, Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock, fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs.
Featured Story: Gap Up Stocks
Want to see what other hedge funds are holding CLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Core Laboratories (NYSE:CLB).
Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.